fda semaglutide news 🎉Exciting that is now approved for MASH (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% Weight-loss GLP-1 pill approved for

If you feel a sudden increase in your heartbeat or palpitations when resting, report these symptoms to your healthcare provider immediately

In the obesity trials, participants on the 12 mg dose reached up to roughly 2829% mean body-weight reduction at 68 to 80 weeks, with a large share crossing the 25% and 30% thresholds, the strongest weight result reported for a GLP-1-class compound in a phase 3 trial [5]

Common side effects are much more likely to include mild nausea, constipation, or indigestion, which are generally manageable and tend to improve over time as your body adjusts

This may reduce, though not eliminate, the risk of rebound weight gain

Ozempic works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, which collectively reduce appetite and caloric intake

Standard course: 1-2 times per week for 4-8 weeks